For: | Li XY, Ji PX, Ni XX, Chen YX, Sheng L, Lian M, Guo CJ, Hua J. Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease. World J Hepatol 2022; 14(7): 1365-1381 [PMID: 36158922 DOI: 10.4254/wjh.v14.i7.1365] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i7/1365.htm |
Number | Citing Articles |
1 |
Giovanni Musso, Francesca Saba, Maurizio Cassader, Roberto Gambino. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances. Progress in Lipid Research 2023; 91: 101238 doi: 10.1016/j.plipres.2023.101238
|
2 |
Xiaoyan Qin, Zhengli Tan, Qi Li, Shiyi Zhang, Dingheng Hu, Denghui Wang, Liangxu Wang, Baoyong Zhou, Rui Liao, Zhongjun Wu, Yanyao Liu. Rosiglitazone attenuates Acute Kidney Injury from hepatic ischemia–reperfusion in mice by inhibiting arachidonic acid metabolism through the PPAR-γ/NF-κB pathway. Inflammation Research 2024; doi: 10.1007/s00011-024-01929-x
|
3 |
Hung Thai Vu, Vien Duc Nguyen, Hiroko Ikenaga, Tsutomu Matsubara. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment. Biomedicines 2024; 12(8): 1876 doi: 10.3390/biomedicines12081876
|
4 |
Pei‐Xuan Ji, Yu‐Xin Chen, Xi‐Xi Ni, Qi Miao, Jing Hua. Effect of triggering receptor expressed on myeloid cells 2‐associated alterations on lipid metabolism in macrophages in the development of non‐alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2024; 39(2): 369 doi: 10.1111/jgh.16417
|
5 |
A. N. Abd Halim, N. A. S. Zikri, Z. Ngaini, N. H. Zamakshshari, Y. K. Wei, D. Noissy Diosing. Synthesis In Silico and ADMET Profile of Triazinethione Derivatives for Their Potential as Anti-Inflammatory Agents. Russian Journal of General Chemistry 2023; 93(11): 2889 doi: 10.1134/S1070363223110208
|